Study Summary
This trial will investigate whether cognitive rehabilitation can help improve cognition for patients with post-COVID-19 cognitive impairment, as well as collect preliminary data on potential connectivity networks underlying the effect of cognitive rehabilitation on cognitive improvements.
Eligible Conditions
- Cognitive Impairment
Treatment Effectiveness
Effectiveness Progress
Study Objectives
8 Primary · 8 Secondary · Reporting Duration: end of study, at 12 months
Month 12
Acceptability Scale
Dropout number
Enrollment yield
NACC battery's abbreviated Multilingual Naming Test (MINT)
NACC battery's verbal phonemic and category fluency tests
National Alzheimer's Coordinating Center (NACC) battery's Number Span
Paced Auditory Serial Addition Task (PASAT)
Resting state functional connectivity (rsFC)
Staff Practicality
The Hopkins Verbal Learning Test-Revised (HVLT-R)
The Symbol Digit Modalities Text (SDMT)
Trail Making Test - Part B
Trail Making Test, Part A
Treatment Credibility and Expectancy Questionnaire.
Wide Range Achievement Test, reading subtest, 4th edition (WRAT-4)
Wisconsin Card Sorting Task (WCST)-64
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Brain Health Education Program
1 of 2
Cognitive Rehabilitation
1 of 2
Active Control
Experimental Treatment
60 Total Participants · 2 Treatment Groups
Primary Treatment: Cognitive Rehabilitation · No Placebo Group · N/A
Cognitive Rehabilitation
Behavioral
Experimental Group · 1 Intervention: Cognitive Rehabilitation · Intervention Types: BehavioralBrain Health Education Program
Behavioral
ActiveComparator Group · 1 Intervention: Brain Health Education Program · Intervention Types: BehavioralTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive Rehabilitation
2009
N/A
~390
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: end of study, at 12 months
Who is running the clinical trial?
Icahn School of Medicine at Mount SinaiLead Sponsor
779 Previous Clinical Trials
482,951 Total Patients Enrolled
Juan Wisnivesky, MD, DrPhPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You have a confirmed SARS-CoV-2 infection.
You must be able to speak English.
You have objective mild to moderate cognitive impairment, which will be defined as impairment in executive function (a z-score >1.5 standard deviations below the normative mean) and in at least one other cognitive domain.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments